Clinical Trials on Hematologic Malignancies in Austria

Total 1086 results

Amgen

Recruiting

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

B Cell Precursor Acute Lymphoblastic Leukemia

Japan, Australia, Spain, United States, Italy, Germany, France, Turkey, Canada, Netherlands, Austria
Pfizer

Completed

Registry For Patients Treated With BeneFix In Usual Care Setting In Germany

Hemophilia B

Germany, Austria
Baxalta now part of Shire

Completed

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Von Willebrand Disease

Netherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden
GlaxoSmithKline

Terminated

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Hypereosinophilic Syndrome

United States, Belgium, Canada, Germany, Italy, France, Australia
AMAG Pharmaceuticals, Inc.

Completed

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients

Anemia

United States
Novartis Pharmaceuticals

Completed

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)

Polycythemia Vera

Hungary, Italy, Belgium, Germany, Spain, Korea, Republic of, Israel, Canada, Turkey, France, Australia, India
bluebird bio

Completed

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

β-thalassemia Major

United States, Australia, Thailand
Melbourne Health

Recruiting

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Plasma Cell Myeloma | Non-hodgkin Lymphoma | Leukemia, Lymphoblastic, Acute, L1 | Leukemia, Lymphoblastic, Acute, L2

Australia
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)

Hemophilia A

United States, Belgium, Spain, Japan, Poland, Australia
Amgen

Completed

Study of Haemodialysis Patients Switching From Aranesp to Biosimilar (SHADE)

Anaemia

Australia, Italy, Poland, Germany, Greece, Bulgaria, Spain
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
German CLL Study Group

Active, not recruiting

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

United States, Canada, Hungary, United Kingdom, Australia, Poland
Cleave Therapeutics, Inc.

Completed

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myeloid Leukemia, in Relapse

United States, Australia
Arbeitsgemeinschaft medikamentoese Tumortherapie
Roche Pharma AG; AstraZeneca

Recruiting

Genomic Testing and Resulting Medical Decisions

Hematologic Neoplasms | Cancer Head Neck | Cancer, Breast | Cancer of Stomach | Cancer of Unknown Origin | Cancer Colorectal | Cancer, Lung | Cancer of Skin | Cancer of Esophagus | Cancer Refractory | Cancer, Bladder | Cancer, Uterus | Cancer Cervix | Cancer Liver | Cancer, Kidney

Austria
AbbVie

Completed

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review (METER)

Myelofibrosis

Argentina, Australia, Brazil, Canada, Colombia, Greece, Italy, Mexico, Poland, Portugal, Romania, Taiwan, Turkey, United States
Incyte Corporation

Completed

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

Canada, United States, Australia
Gracell Biopharmaceuticals, Inc.

Recruiting

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States
Pfizer

Completed

Study Evaluating Pharmacovigilance Of Refacto AF

Hemophilia A

Germany, Austria
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland
K-Group Alpha, Inc., a wholly owned subsidiary...

Recruiting

Phase 1 First in Human Study of ZN-d5 as a Single Agent

Acute Myeloid Leukemia | Non Hodgkin Lymphoma

Croatia, Australia, Bulgaria, Korea, Republic of, Ukraine, Poland, Spain
Blueprint Medicines Corporation

Active, not recruiting

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States, Canada, United Kingdom, France, Netherlands, Italy, Spain, Austria, Denmark, Germany, Norway, Poland
Ariad Pharmaceuticals

Completed

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)

Carcinoma | Lung Cancer | Non-small Cell Lung Cancer | Advanced Malignancies

United States, Canada, Germany, Spain, Taiwan, Korea, Republic of, Switzerland, Hong Kong, Singapore, Italy, Sweden, United Kingdom, France, Netherlands, Denmark, Australia, Norway, Austria, Luxembourg
Arbeitsgemeinschaft medikamentoese Tumortherapie
Medical University of Vienna; Sanofi; Assign Data Management and Biostatistics... and other collaborators

Recruiting

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Newly Diagnosed Multiple Myeloma

Austria, Greece, Serbia
Bayside Health
Monash University

Recruiting

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Lymphoma, Non-Hodgkin | Multiple Myeloma | HIV | Chronic Lymphocytic Leukemia | Organ Transplantation | COVID-19 Vaccines

Australia
Ichnos Sciences SA

Recruiting

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia
Incyte Corporation

Completed

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

MPN (Myeloproliferative Neoplasms)

United States, Canada, Australia
Amgen

Completed

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia
Bristol-Myers Squibb

Completed

Dasatinib in Combination With Revlimid (and Dexamethasone)

Multiple Myeloma

United States, France, Australia
Incyte Corporation

Completed

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States, Netherlands, Austria
Bioverativ, a Sanofi company

Completed

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza)

Cold Agglutinin Disease

United States, United Kingdom, Israel, Australia, Spain, Austria, Germany, France, Belgium, Japan, Canada, Netherlands, Italy, Norway
Wuerzburg University Hospital
ClinAssess GmbH; Arbeitsgemeinschaft medikamentoese Tumortherapie

Active, not recruiting

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Newly Diagnosed Multiple Myeloma

Germany, Austria
Hoffmann-La Roche

Completed

A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Anemia

Italy, Spain, Sweden, Hong Kong, Greece, Ireland, United Kingdom, Portugal, Taiwan, Turkey, France, Germany, Russian Federation, Belgium, Austria, Thailand, Poland, Czech Republic, Denmark, Finland, Norway, Mexico
Genentech, Inc.

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Australia, Israel
PX Biosolutions

Completed

Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

Cervical Cancer | Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Ovarian Serous Adenocarcinoma | Undifferentiated Carcinoma of Ovary | Cervical Intraepithelial Neoplasia, Grade 3

Australia
Rigel Pharmaceuticals

Enrolling by invitation

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Warm Antibody Autoimmune Hemolytic Anemia

Spain, United States, Australia, Norway, Belarus, Germany, Netherlands, Belgium, Austria, Bulgaria, Czechia, France, Georgia, Italy, Russian Federation, Serbia, Ukraine, United Kingdom
European Society for Blood and Marrow Transplantation

Active, not recruiting

Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

Central Nervous System Infections | Blood Disease | Infection | Blood Cancer | Central Nervous System Complication | Infectious Disease of Nervous System

Australia, Spain, Italy, Germany, France, Colombia, Hungary, Poland, Russian Federation, Tunisia, Turkey
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Novartis Pharmaceuticals

Completed

An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)

Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia

Australia
Ionis Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Beta Thalassemia Intermedia

Australia, Thailand, Greece, Lebanon, Turkey
Octapharma

Completed

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

Austria, United Kingdom, Bulgaria, Hungary, Germany, Poland, Romania, Slovakia
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
Radboud University Medical Center

Recruiting

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (EUMDS)

Myelodysplastic Syndromes (MDS)

Denmark, Switzerland, Serbia, Austria, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

Israel, Sweden, United Kingdom, Germany, Switzerland, France, Spain, Italy, Thailand, Denmark, United States, Poland, Finland, Singapore, Australia, Austria
Bristol-Myers Squibb

Completed

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Australia, Italy, Canada, United States, Germany, Spain, France
Imago BioSciences, Inc., a subsidiary of Merck...

Active, not recruiting

Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Primary Myelofibrosis | Thrombocythemia, Essential

United States, Australia, Hong Kong, Germany, Italy, New Zealand, United Kingdom
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
University of Wuerzburg

Unknown

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

Multiple Myeloma

Germany, Austria
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark

Clinical Trials on Hematologic Malignancies in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations